Genomics

Dataset Information

0

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient Mesothelioma


ABSTRACT: More than half of malignant mesothelioma patients show alterations in the BAP1 tumour suppressor gene. Being a member of the Polycomb repressive deubiquitinating (PR-DUB) complex, BAP1 loss results in an altered epigenome which may create new vulnerabilities that remain largely unknown. Here we performed a CRISPR/Cas9-kinome screen in mesothelioma cells that identified two kinases in the Mevalonate/Cholesterol biosynthesis pathway. Furthermore, our analysis of chromatin, expression and genetic perturbation data in mesothelioma cells suggests a dependency on Polycomb repressive complex 2 (PRC2) mediated silencing. Pharmacological inhibition of PRC2 elevates the expression of cholesterol biosynthesis genes only in BAP1-deficient mesothelioma, thereby sensitizing these cells to the combined targeting of PRC2 and the mevalonate pathway. Finally, by subjecting autochthonous Bap1-deficient mesothelioma mice or xenografts to mevalonate pathway inhibition (Zoledronic Acid) and PRC2 inhibition (Tazemetostat), we demonstrate a potent anti-tumour effect, suggesting a targeted combination therapy for Bap1-deficient mesothelioma

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE222376 | GEO | 2023/01/12

REPOSITORIES: GEO

Similar Datasets

2021-06-27 | GSE162739 | GEO
2015-10-05 | GSE61360 | GEO
2022-09-15 | PXD028470 | JPOST Repository
2019-01-28 | PXD011808 | Pride
2011-05-19 | E-GEOD-29383 | biostudies-arrayexpress
2011-05-19 | E-GEOD-29354 | biostudies-arrayexpress
2011-09-25 | E-GEOD-29902 | biostudies-arrayexpress
2020-08-07 | PXD014290 | Pride
2021-09-22 | PXD020684 | Pride
2016-11-15 | GSE85751 | GEO